UPLIZNA
Q2 2026 sales rose 90% to $335 million; a Phase 3 study in CIDP is due to start between H2 2026 and H1 2027.
The numbers
UPLIZNA product sales$335 millionQ2 2026 · up 90% year over year · source ↗
What it is
Antibody treatment for neuromyelitis optica spectrum disorder, a rare neurological autoimmune disease. Amgen is testing it in chronic inflammatory demyelinating polyneuropathy (CIDP) and other indications.
Why it matters to the stock. UPLIZNA is one of the fastest-growing products in Amgen's portfolio. New indications would extend its growth beyond its rare-disease base.
News
No stories tagged to this project yet.